Vantage Consulting Group Inc Gilead Sciences, Inc. Transaction History

Vantage Consulting Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $26,207 - $30,245	415 Added 13.12%	3,577 $245,000
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $14,172 - $17,283	198 Added 6.68%	3,162 $231,000
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $6,301 - $7,145	-86 Reduced 2.82%	2,964 $240,000
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $7,985 - $8,712	108 Added 3.67%	3,050 $228,000
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $5,244 - $5,982	-69 Reduced 2.29%	2,942 $226,000
Q1 2023 May 10, 2023	BUY	$77.31 - $88.08 $20,487 - $23,341	265 Added 9.65%	3,011 $249,000
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $74,347 - $106,737	-1,193 Reduced 30.29%	2,746 $235,000
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $1,309 - $1,496	-22 Reduced 0.56%	3,939 $243,000
Q2 2022 Aug 09, 2022	BUY	$57.72 - $65.01 $230 - $260	4 Added 0.1%	3,961 $245,000
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $15,001 - $18,798	259 Added 7.0%	3,957 $235,000
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $17,193 - $19,514	265 Added 7.72%	3,698 $269,000
Q3 2021 Nov 10, 2021	BUY	$67.69 - $73.03 $9,002 - $9,712	133 Added 4.03%	3,433 $240,000
Q2 2021 Aug 11, 2021	BUY	$63.47 - $69.35 $209,451 - $228,854	3,300 New	3,300 $227,000
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $71,940 - $82,083	-1,199 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $67,923 - $77,395	1,199 New	1,199 $70,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vantage Consulting Group Inc with notifications on news.